Melflufen for relapsed and refractory multiple myeloma

References

• Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med. 2004;351(18):1860–1873.
   PubMed Web of Science ®Google Scholar
• Howlader NNA, Krapcho M, Miller D, et al. (eds). SEER Cancer Statistics Review, 1975-2016. Bethesda (MD): National Cancer Institute. https://seer.cancer.gov/csr/1975_2016/,basedonNovember2018SEERdatasubmission,postedtotheSEERwebsite,April2019. https://seercancergov/statfacts/html/mulmyhtmlAccessedJan28, 2020
   Google Scholar
• Hussein MA. Multiple myeloma: most common end-organ damage and management. J Natl Compr Canc Netw. 2007;5(2):170–178.
   PubMedGoogle Scholar
• Keats JJ, Chesi M, Egan JB, et al. Clonal competition with alternating dominance in multiple myeloma. Blood. 2012;120(5):1067–1076.
   PubMed Web of Science ®Google Scholar
• Robak P, Drozdz I, Szemraj J, et al. Drug resistance in multiple myeloma. Cancer Treat Rev. 2018;70:199–208.
   PubMed Web of Science ®Google Scholar
• Moreau P, San Miguel J, Sonneveld P, et al. Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv52–iv61.
   PubMed Web of Science ®Google Scholar
• Moreau P, Mateos MV, Berenson JR, et al. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. Lancet Oncol. 2018;19(7):953–964.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Dytfeld D, Grosicki S, et al. Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma. N Engl J Med. 2018;379(19):1811–1822.
   PubMed Web of Science ®Google Scholar
• Facon T, Kumar S, Plesner T, et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med. 2019;380(22):2104–2115.
   PubMed Web of Science ®Google Scholar
• Mateos MV, Dimopoulos MA, Cavo M, et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med. 2018;378(6):518–528.
   PubMed Web of Science ®Google Scholar
• San-Miguel JF, Hungria VT, Yoon SS, et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol. 2014;15(11):1195–1206.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Hungria VT, Yoon SS, et al. Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment. Blood. 2016;127(6):713–721.
   PubMed Web of Science ®Google Scholar
• Popat R, Brown SR, Flanagan L, et al. Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial. Lancet Haematol. 2016;3(12):e572–e580.
   PubMed Web of Science ®Google Scholar
• Oriol A, Abril L, Ibarra G, et al. Limited treatment options in refractory multiple myeloma: promising therapeutic developments. Expert Rev Anticancer Ther. 2020;20(1):31–44.
   PubMed Web of Science ®Google Scholar
• Pour L, Efebera YA, Granell M, et al. ANCHOR (OP-104): A phase 1 study update of melflufen and dexamethasone plus bortezomib or daratumumab in relapsed/refractory multiple myeloma patients refractory to an IMiD or a proteasome inhibitor. HemaSphere. 2019;3(S1):739. (Abstract PF608).
   Google Scholar
• Naymagon L, Abdul-Hay M. Novel agents in the treatment of multiple myeloma: a review about the future. J Hematol Oncol. 2016;9(1):52.
   PubMed Web of Science ®Google Scholar
• Wickstrom M, Nygren P, Larsson R, et al., Melflufen - a peptidase-potentiated alkylating agent in clinical trials. Oncotarget. 2017;8(39):66641–66655.
   PubMedGoogle Scholar
• Richardson P, Bringhen S, Voorhees P, et al. Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): A multicentre, international, open-label, phase 1–2 study. Lancet Haematol. 2020;7(5):e395–e407.
   PubMed Web of Science ®Google Scholar
• Mateos MV, Oriol A, Larocca A, et al. Clinical activity of melflufen in patients with triple-class refractory multiple myeloma and poor-risk features in an updated analysis of HORIZON (OP-106), a phase 2 study in patients with relapsed/refractory multiple myeloma refractory to pomalidomide and/or daratumumab. Poster presented at: 61st American Society of Hematology Annual Meeting and Exposition; 2019 Dec 7-10; Orlando (FL). Abstract 1883.
   Google Scholar
• Ocio EM, Efebera YA, Granell M, et al. ANCHOR (OP-104): updated efficacy and safety from a phase 1/2 study of melflufen and dexamethasone plus bortezomib or daratumumab in patients with relapsed/refractory multiple myeloma (RRMM) refractory to an IMiD or a proteasome inhibitor (PI). Poster presented at: 61st American Society of Hematology Annual Meeting and Exposition; 2019 Dec 7-10; Orlando (FL). Abstract 3124.
   Google Scholar
• Kastritis E, Palumbo A, Dimopoulos MA. Treatment of relapsed/refractory multiple myeloma. Semin Hematol. 2009;46(2):143–157.
   PubMed Web of Science ®Google Scholar
• Lokhorst HM, Plesner T, Laubach JP, et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med. 2015;373(13):1207–1219.
   PubMed Web of Science ®Google Scholar
• Chim CS, Kumar SK, Orlowski RZ, et al., Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond. Leukemia. 2018;32(2):252–262.
   PubMed Web of Science ®Google Scholar
• Mateos MV, Spencer A, Nooka AK, et al. Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies. Haematologica. 2020;105(2):468–477.
   PubMed Web of Science ®Google Scholar
• Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015;373(7):621–631.
   PubMed Web of Science ®Google Scholar
• Pawlyn C, Kaiser M, Davies F, et al. Efficacy of quadruplet KCRD (carfilzomib, cyclophosphamide, lenalidomide, and dexamethasone) induction for newly diagnosed myeloma patients: analysis of the Myeloma XI study by molecular risk. HemaSphere. 2019;3(S1):391. (Abstract S873).
   Google Scholar
• Cejalvo MJ, de la Rubia J. Which therapies will move to the front line for multiple myeloma? Expert Rev Hematol. 2017;10(5):383–392.
   PubMed Web of Science ®Google Scholar
• Moreau P, Zamagni E, Mateos MV. Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide. Blood Cancer J. 2019;9(4):38.
   PubMed Web of Science ®Google Scholar
• Moreau P. How I treat myeloma with new agents. Blood. 2017;130(13):1507–1513.
   PubMed Web of Science ®Google Scholar
• Gandhi UH, Cornell RF, Lakshman A, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019;33(9):2266–2275.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Dimopoulos MA, Kastritis E, et al., Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. Leukemia. 2017;31(11):2443–2448.
   PubMed Web of Science ®Google Scholar
• Schjesvold F, Robak P, Pour L, et al. OCEAN: a randomized phase III study of melphalan flufenamide + dexamethasone to treat relapsed refractory multiple myeloma. Future Oncol. 2020;16(11):631–641.
   PubMed Web of Science ®Google Scholar
• Lonial S, Lee HC, Badros A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020;21(2):207–221.
   PubMed Web of Science ®Google Scholar
• Chari A, Vogl DT, Gavriatopoulou M, et al. Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. N Engl J Med. 2019;381(8):727–738.
   PubMed Web of Science ®Google Scholar
• Karyopharma. Press release. Karyopharm announces FDA approval of XPOVIO™ (selinexor) for the treatment of patients with relapsed or refractory multiple myeloma. 2019 [January 10; cited 2020 Apr 21]. Available from: https://investors.karyopharm.com/news-releases/news-release-details/karyopharm-announces-fda-approval-xpoviotm-selinexor-treatment
   Google Scholar
• Raje N, Berdeja J, Lin Y, et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019;380(18):1726–1737.
   PubMed Web of Science ®Google Scholar
• Squibb B-M Press release. Bristol-myers squibb and bluebird bio announce positive top-line results from the pivotal phase 2 karmma study of ide-cel in relapsed and refractory multiple myeloma. 2019 [2020 Mar 6; cited 2020 Apr 21]. Available from: https://news.bms.com/press-release/corporatefinancial-news/bristol-myers-squibb-and-bluebird-bio-announce-positive-top-li
   Google Scholar
• Berdeja JG, Alsina M, Shah ND, et al. Updated results from an ongoing phase 1 clinical study of bb21217 anti-BCMA CAR T cell therapy. Blood. 2019;134(Supplement_1): Abstract 927.
   PubMedGoogle Scholar
• Trudel S, Lendvai N, Popat R, et al. Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial. Lancet Oncol. 2018;19(12):1641–1653.
   PubMed Web of Science ®Google Scholar
• U.S. National Library of Medicine ClinicalTrials.gov. Study of CC-93269, a BCMA x CD3 T cell engaging antibody, in subjects with relapsed and refractory multiple myeloma. 2018 [cited 2020 Apr 21]. Available from: https://clinicaltrials.gov/ct2/show/NCT03486067
   Google Scholar
• U.S. National Library of Medicine ClinicalTrials.gov. First in Human (FIH) Study of REGN5458 in patients with relapsed or refractory multiple myeloma. 2018 [cited 2020 Apr 21]. Available from: https://clinicaltrials.gov/ct2/show/NCT03761108
   Google Scholar
• U.S. National Library of Medicine ClinicalTrials.gov. Assessment of AMG 420 in subjects with relapsed and/or refractory multiple myeloma (AMG420) 2019 [cited 2020 Apr 21]. Available from: https://clinicaltrials.gov/ct2/show/NCT03836053
   Google Scholar
• Topp MS, Duell J, Zugmaier G, et al. Anti-B-cell maturation antigen BiTE molecule AMG 420 induces responses in multiple myeloma. J Clin Oncol. 2020;38(8):775–783.
   PubMed Web of Science ®Google Scholar
• Costa LJ, Wong SW, Bermúdez A, et al. First clinical study of the B-cell maturation antigen (BCMA) 2+1 T cell engager (TCE) CC-93269 in patients (pts) with relapsed/refractory multiple myeloma (RRMM): interim results of a phase 1 multicenter trial. Blood. 2019;134(Supplement_1): Abstract 143. DOI:10.1182/blood-2019-122895.
   PubMedGoogle Scholar
• Cooper D, Madduri D, Lentzsch S, et al. Safety and preliminary clinical activity of REGN5458, an anti-BCMA x anti-CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma. Poster presented at: The 61st American Society of Hematology Annual Meeting; 2019 Dec 7-10; Orlando (FL). Abstract 3176.
   Google Scholar
• Chauhan D, Ray A, Viktorsson K, et al. In vitro and in vivo antitumor activity of a novel alkylating agent, melphalan-flufenamide, against multiple myeloma cells. Clin Cancer Res. 2013;19(11):3019–3031.
   PubMed Web of Science ®Google Scholar
• Hitzerd SM, Verbrugge SE, Ossenkoppele G, et al. Positioning of aminopeptidase inhibitors in next generation cancer therapy. Amino Acids. 2014;46(4):793–808.
   PubMed Web of Science ®Google Scholar
• Moore HE, Davenport EL, Smith EM, et al. Aminopeptidase inhibition as a targeted treatment strategy in myeloma. Mol Cancer Ther. 2009;8(4):762–770.
   PubMed Web of Science ®Google Scholar
• Wickström M, Larsson R, Nygren P, et al. Aminopeptidase N (CD13) as a target for cancer chemotherapy. Cancer Sci. 2011;102(3):501–508.
   PubMed Web of Science ®Google Scholar
• Wickström M, Viktorsson K, Lundholm L, et al. The alkylating prodrug J1 can be activated by aminopeptidase N, leading to a possible target directed release of melphalan. Biochem Pharmacol. 2010;79(9):1281–1290.
   PubMed Web of Science ®Google Scholar
• Gullbo J, Wickstrom M, Tullberg M, et al. Activity of hydrolytic enzymes in tumour cells is a determinant for anti-tumour efficacy of the melphalan containing prodrug J1. J Drug Target. 2003;11(6):355–363.
   PubMed Web of Science ®Google Scholar
• Ray A, Ravillah D, Das DS, et al. A novel alkylating agent Melflufen induces irreversible DNA damage and cytotoxicity in multiple myeloma cells. Br J Haematol. 2016;174(3):397–409.
   PubMed Web of Science ®Google Scholar
• Slipicevic A, Munawar U, Aschan J, et al. Melflufen efficacy in multiple myeloma with TP53 aberrations. Poster presented at: American Association for Cancer Research (AACR) Annual Meeting; 2020 Jun 22-24; Virtual Annual Meeting II. 2020. Abstract 1843.
   Google Scholar
• Wickström M, Haglund C, Lindman H, et al. The novel alkylating prodrug J1: diagnosis directed activity profile ex vivo and combination analyses in vitro. Invest New Drugs. 2008;26(3):195–204.
   PubMed Web of Science ®Google Scholar
• Chesi M, Matthews GM, Garbitt VM, et al. Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy. Blood. 2012;120(2):376–385.
   PubMed Web of Science ®Google Scholar
• Berglund A, Ullen A, Lisyanskaya A, et al. First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies. Invest New Drugs. 2015;33(6):1232–1241.
   PubMed Web of Science ®Google Scholar
• Oncopeptides. Summary – our clinical studies. 2020 [cited 2020 Apr 21]. Available from: https://oncopeptides.se/en/our-clinical-trials-summary/
   Google Scholar
• Laubach J, Richardson P, Anderson K. Multiple myeloma. Annu Rev Med. 2011;62:249–264.
   PubMed Web of Science ®Google Scholar
• Paner A, Okwuosa TM, Richardson KJ, et al. Triplet therapies - the new standard of care for multiple myeloma: how to manage common toxicities. Expert Rev Hematol. 2018;11(12):957–973.
   PubMed Web of Science ®Google Scholar
• Parameswaran R, Lunning M, Mantha S, et al. Romiplostim for management of chemotherapy-induced thrombocytopenia. Support Care Cancer. 2014;22(5):1217–1222.
   PubMed Web of Science ®Google Scholar
• Oncopeptides. Oncopeptides to apply for accelerated approval in the US. 2020 [cited 2020 Apr 21]. Available from: https://oncopeptidesse/en/oncopeptides-to-apply-for-accelerated-approval-in-the-us/
   Google Scholar
• Oncopeptides. FDA grants priority review of melflufen for patients with triple-class refractory multiple myeloma. [cited 2020 Sep 15]. Available from: https://oncopeptides.se/en/fda-grants-priority-review-of-melflufen-for-patients-with-triple-class-refractory-multiple-myeloma/
   Google Scholar
• Richardson PG, San Miguel JF, Moreau P, et al. Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting. Blood Cancer J. 2018;8(11):109.
   PubMed Web of Science ®Google Scholar